TIM3
Showing 1 - 25 of 746
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)
Recruiting
- Acute Myeloid Leukemia Refractory
- Acute Myeloid Leukemia, in Relapse
- anti Tim-3/CD123 CAR-T cell therapy
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 4, 2023
Hepatocellular Carcinoma Trial in Beijing (Autologous RAK cells)
Recruiting
- Hepatocellular Carcinoma
- Autologous RAK cells
-
Beijing, Beijing, ChinaBeijing Hospital Center of Biotherapy
Feb 13, 2023
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell
Not yet recruiting
- Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
- +2 more
- Biopsy
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 28, 2023
Pre-Eclampsia Trial (real time PCR)
Not yet recruiting
- Pre-Eclampsia
- real time PCR
- (no location specified)
Mar 22, 2022
TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System
Completed
- Lymphoma, B-Cell
-
Montpellier, FranceUh Montpellier
Nov 12, 2021
Solid Tumor, Lymphoma Trial (LB1410)
Recruiting
- Solid Tumor
- Lymphoma
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Dec 27, 2022
Melanoma Stage III, Melanoma Stage IV Trial in Washington, Boston, Pittsburgh (Dostarlimab (TSR-042) (singly), Dostarlimab
Recruiting
- Melanoma Stage III
- Melanoma Stage IV
- Dostarlimab (TSR-042) (singly)
- Dostarlimab (TSR-042) and TSR-022 (combination)
-
Washington, District of Columbia
- +2 more
Feb 22, 2022
Adult Primary Liver Cancer, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer Trial in
Recruiting
- Adult Primary Liver Cancer
- +2 more
- TSR-022 and TSR-042
-
Honolulu, HawaiiUniversity of Hawaii
Sep 22, 2021
Metastatic Cancer, Solid Tumor Trial in Worldwide (Sym021, Sym022, Sym023)
Active, not recruiting
- Metastatic Cancer
- Solid Tumor
- Sym021
- +3 more
-
Aurora, Colorado
- +17 more
Sep 8, 2022
Advanced or Metastatic Esophageal Squamous Cell Carcinoma Trial in Worldwide (RO7121661, RO7247669, Nivolumab)
Recruiting
- Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- RO7121661
- +2 more
-
Buenos Aires, Argentina
- +79 more
Aug 3, 2022
The Status of Immune Checkpoints at Gastrointestinal Cancer
Completed
- Gastrointestinal Cancer
- Flow cytometric analysis
-
Istanbul, TurkeyIstanbul Training and Reseach Hospital
Dec 4, 2022
Immune Checkpoints in Intraabdominal Ascites Fluid
Completed
- Colorectal Cancer
- Flow-cytometric analysis
-
Istanbul, TurkeyUfuk Oguz Idiz
Dec 4, 2022
Advanced Solid Tumor Trial in China (TQB2618 injection and TQB2450 injection)
Recruiting
- Advanced Solid Tumor
- TQB2618 injection and TQB2450 injection
-
Fuzhou, Fujian, China
- +4 more
Dec 1, 2022
Metastatic Melanoma Trial in New Haven (Tumor Infiltrating Lymphocytes, Nivolumab and Ipilimumab)
Terminated
- Metastatic Melanoma
- Tumor Infiltrating Lymphocytes
- Nivolumab and Ipilimumab
-
New Haven, ConnecticutYale New Haven Hospital
Jul 20, 2022
Autoimmune Diseases, Multiple Sclerosis Trial in Amman (LPX-TI641)
Not yet recruiting
- Autoimmune Diseases
- Multiple Sclerosis
-
Amman, JordanTriumpharma
May 11, 2023
Advanced Esophageal Squamous Cell Carcinoma Trial in China (TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin,
Not yet recruiting
- Advanced Esophageal Squamous Cell Carcinoma
- TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin
- +2 more
-
Tongling, Anhui, China
- +9 more
Apr 18, 2023